Farnesyltransferase inhibitors

Seminars in Oncology

Volumn 28, Issue 5 SUPPL. 16, 2001, Pages 86-93

  Hahn, Stephen M ^a   Bernhard, Eric ^a   McKenna, W Gillies ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; BIOLOGICAL MARKER; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; L 778123; LAMIN A; LAMIN B; LONAFARNIB; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; TIPIFARNIB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ASSAY; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; CYTOTOXICITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; ENZYME INHIBITION; GENE MUTATION; HUMAN; MAXIMUM TOLERATED DOSE; ONCOGENE RAS; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN MODIFICATION; SIGNAL TRANSDUCTION; TOXICITY; TREATMENT OUTCOME;

EID: 0035171291     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.28559     Document Type: Conference Paper

References (40)

1. The hallmarks of cancer
2. Ras oncogenes in human cancer: A review
3. Ras protein farnesyl transferase: A strategic target for anticancer therapeutic development
4. Aberrant function of the Ras signal transduction pathway in human breast cancer
5. Overexpression of the Ras-related TC21/R-Ras 2 protein may contribute to the development of human breast cancers
6. Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2
7. Ras activation in human breast cancer
8. Human breast carcinoma desmoplasia is PDGF initiated
9. Function and regulation of ras
10. Ras genes
11. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity
12. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro
13. Ras regulatory interactions: Novel targets for anti-cancer intervention?
14. Farnesyl transferase inhibitors: Ras research yields a potential cancer therapeutic
15. Ras farnesyl transferase: A new therapeutic target
16. Proliferation of human malignant astrocytomas is dependent on Ras activation
17. Non-Ras targets of farnesyltransferase inhibitors: Focus on Rho
18. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity
19. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer
20. R115777, a novel imidazole farnesyl protein transferase inhibitor (FTI): Biochemical and cellular effects in H-ras and K-ras dominant systems
21. R115777, a selective farnesyl protein transferase inhibitor (FTI), induces anti-angiogenic, apoptotic and anti-proliferative activity in CAPAN-2 and LoVo tumor xenografts
22. R115777, a novel imidazole farnesyl protein transferase inhibitor (FTI) with potent oral antitumor activity
23. Phase I and pharmacologic study with the novel farnesyltransferase inhibitor (FTI) R115777
24. A phase I and pharmacokinetic (PK) study of the farnesyltransferase inhibitor R115777 in combination with gemcitabine (Gem)
25. Phase-I combination trial of the farnesyltransferase inhibitor (FTI) R115777 with a 5FU/LV regimen in advanced colorectal (CRC) or pancreatic (PC) cancer
26. A phase II study of farnesyl transferase inhibitor R115777 in patients with advanced breast cancer
27. BMS-214662, a highly potent apoptotic farnesyltransferase inhibitor
28. Phase I clinical trial of the farnesyltransferase (FT) inhibitor BMS-214662 in patients with advanced solid tumors
29. Pharmaco-kinetics (PK) and pharmacodynamics (PD) of the farnesyl-transferase (FT) inhibitor BMS-214662 in patients with advanced solid tumors
30. Novel tricyclic inhibitors of farnesyl transferase protein: Biochemical characterization and inhibition of Ras modification in transfected Cos cells
31. Antitumor activity of SCH66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice
32. A phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity
33. Phase I and pharmacokinetic study of SCH66336, a novel FPTI, using a 2-week on, 2-week off schedule
34. Phase I and pharmacologic study of continuous daily oral SCH 66336, a novel farnesyl transferase inhibitor in patients with solid tumors
35. Phase I pharmacokinetic trial of the farnesyl transferase inhibitor SCH66336 plus gemcitabine in advanced cancers
36. The farnesyl protein transferase (FPTase) inhibitor L-778,123 in patients with solid cancers
37. Phase I trial of the farnesyl protein transferase (FPTase) inhibitor L-778 123 on a 14 or 28-day dosing schedule
38. A phase I and PK study of farnesyl transferase inhibitor L-778,123 administered as a seven day continuous infusion in combination with paclitaxel
39. Comparison of potential markers of farnesyl transferase inhibition
40. A farnesyl-protein transferase inhibitor induces p 21 expression and G1 block in p53 wild type tumor cells